eISSN: 2084-9869
ISSN: 1233-9687
Polish Journal of Pathology
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank
2/2022
vol. 73
 
Share:
Share:
more
 
 
abstract:
Original paper

Immunohistochemical evaluation of forkhead box A1 and EphA5 markers in serous ovarian carcinomas, and their impact on the clinical outcome of patients

Nehal S Abouhashem
1
,
Ola Harb
1
,
Amira Elwan
2
,
Mohamed Moustafa Zaitoun
3
,
Yasser S Saraya
3

1.
Pathology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt
2.
Clinical Oncology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt
3.
Obstetrics and Gynaecology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt
Pol J Pathol 2022; 73 (2): 120-133
Online publish date: 2022/10/10
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
PlumX metrics:
Ovarian cancer is the most lethal gynaecological neoplasm in females. In ovarian cancer, forkhead box A1 (FOXA1) aids transcription of YAP-associated protein mediated by the cyclic adenosine monophosphate response element-binding protein. As a result, cellular proliferation and migration increased. The roles of erythropoietin-producing human hepatocellular carcinoma cell (Eph) receptors and ephrin ligands in cell adhesion, migration, cell proliferation regulation in various cancers, and angiogenesis are well characterized.

This study included formalin-fixed, paraffin-embedded tissue specimens from 41 patients with ovarian serous cystadenocarcinoma, including both low- and high-grade tumours. For each case, a paraffin block with tumour tissue was chosen for an immunohistochemical procedure using primary antibodies against EphA5 and FOXA1. By the end of 2017, patients finished their chemotherapy and were followed for the next 3 years.

Positive FOXA1 and EphA5 results were presented in 68.3% and 39% of patients, respectively. A statistically significant correlation was detected between FOXA1 expression and each of CA-125 level, tumour stage, tumour grade, and the presence of lymph node metastasis. In our work, the overall survival was positively correlated with EphA5 expression and inversely correlated to FOXA1 immunoreactivity. The estimated disease-free survival (DFS) and EphA5 immunoreactivity had a significant positive association, whereas DFS and FOXA1 protein expression had a significant inverse link.

FOXA1 and EphA5 expression play a role in ovarian cancer progression and prognosis prediction.
keywords:

FOXA1, EphA5, serous ovarian carcinomas

Quick links
© 2022 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.